Edwards Lifesciences (EW) stock faces a downgrade at Wolfe due to concerns over its TAVR market prospects. Read more here.

GlobalData analysts anticipate FDA approval for the JenaValve Trilogy TAVR device designed to treat aortic regurgitation (AR) ...

Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter ...

Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...

Brighton Jones LLC purchased a new position in Edwards Lifesciences Co. (NYSE:EW – Free Report) in the fourth quarter, ...

These techniques include coronary sinus annuloplasty, direct annuloplasty, leaflet repair ... (Edwards Lifesciences, Inc., CA, USA) valve is a balloon-expandable, bovine pericardial interventional ...

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”) ...

Edwards Lifesciences Corporation (NYSE ... As we noted earlier this year, the Company's flagship transcatheter aortic valve replacement (TAVR) franchise slowed as compared to the Company's recent ...

HB Wealth Management LLC lowered its position in shares of Edwards Lifesciences Co. (NYSE:EW – Free Report) by 5.3% in the ...

Cardiac device innovations made waves in 2024, with regulatory approvals, clinical breakthroughs, and product launches ...